BBIO
BridgeBio Pharma, Inc.
Overview
BridgeBio Pharma develops medicines for patients with genetic diseases, with a commercial-stage portfolio including the FDA-approved product Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and multiple late-stage candidates in rare genetic conditions.
BridgeBio Pharma, Inc is a Healthcare company operating in Biotechnology with a $12.98B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
5 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $-0.63—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $-0.63 | — | — | — | — | EODHD |
Source: EODHD. BBIO reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks BBIO's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.55 | $3.21 | +41.9% | -0.2% | -3.0% |
| Q4 FY2026 | $4.38 | $3.20 | +37.0% | -5.5% | -6.6% |
| Q3 FY2026 | $4.55 | $3.33 | +36.6% | +0.9% | +1.5% |
| Q2 FY2026 | $4.50 | $3.31 | +36.1% | -7.1% | -5.1% |
| Q1 FY2025 | $4.76 | $3.42 | +39.3% | -7.6% | -10.0% |
| Q4 FY2025 | $4.90 | $3.32 | +47.5% | -2.7% | -0.4% |
| Q3 FY2025 | $4.72 | $3.34 | +41.4% | -1.0% | -1.0% |
| Q2 FY2025 | $5.14 | $3.49 | +47.4% | -5.3% | -7.4% |
| Q1 FY2024 | $5.02 | $3.51 | +43.1% | -4.9% | -3.5% |
| Q4 FY2024 | $5.03 | $3.34 | +50.7% | -7.0% | -9.7% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Neil KumarCEO10 mo5 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
- Thomas TrimarchiCFO10 mo5 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- Maricel ApuliChief Accounting Officer10 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BBIO.
$ curl https://api.spokenalpha.com/v1/companies/BBIOFAQ
Frequently asked about BBIO
Where can I find BridgeBio Pharma, Inc.'s (BBIO) earnings call transcripts?
Spoken Alpha indexes BBIO's earnings call transcripts at https://spokenalpha.com/companies/BBIO. Each call links to attributed speakers and parsed analyst Q&A. BridgeBio Pharma, Inc.'s own investor relations page is at https://investor.bridgebio.com/overview/default.aspx.
When was BridgeBio Pharma, Inc.'s most recent earnings call?
BridgeBio Pharma, Inc. (BBIO) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is BBIO in?
BridgeBio Pharma, Inc. (BBIO) operates in the Healthcare sector (Biotechnology industry).